Form 4: Werewolf Therapeutics Director Sells Shares

Luke Evnin, a Director at Werewolf Therapeutics, reported the sale of common stock totaling 192,362 shares across multiple transactions between May 21 and May 26, 2026, pursuant to a Rule 10b5-1 trading plan.

Summary

• Luke Evnin, a Director at Werewolf Therapeutics, Inc. (HOWL), has reported transactions involving the sale of common stock.
• These sales occurred on May 21, May 22, and May 26, 2026.
• A total of 192,362 shares were sold.
• The transactions were executed under a Rule 10b5-1 trading plan established on March 26, 2026.
• The sales involved various entities managed or associated with the reporting person, including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BIoVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, and MPM Oncology Innovations Fund, L.P.
• The weighted average sale prices ranged from $0.4126 to $0.4826 per share.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to a director selling a substantial number of shares, even if executed under a pre-planned trading strategy.

Negatives

• Director Luke Evnin sold a significant number of shares (192,362) over a short period.
• The sales occurred at prices ranging from $0.4126 to $0.4826, indicating a potentially low valuation or market sentiment at the time of sale.

Risks

• The sales were conducted under a Rule 10b5-1 plan, which is designed to provide an affirmative defense against allegations of insider trading. However, the execution of such a plan can still be interpreted negatively by the market.
• The specific entities involved in the sales and the disclaimer of beneficial ownership except to the extent of pecuniary interest suggest complex ownership structures that could be subject to scrutiny.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports past transactions.

Management Comments

• The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, can sometimes signal a lack of confidence from management or directors in the company's near-term prospects, especially in the biotechnology sector where valuations can be volatile.

Related Party Transactions

• The sales involved multiple entities associated with the reporting person, including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BIoVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, and MPM Oncology Innovations Fund, L.P. Luke Evnin is a member of AM LLC and a Managing Director of BV LLC, indicating related party involvement in the transactions.

Stakeholder Impact

• Shareholders may view the director's sale of shares negatively, potentially impacting share price due to perceived lack of confidence.
• Employees and other stakeholders might interpret the sales as a sign of potential future challenges for the company.

Key Dates

Recommendation

While the sale by a director is a negative signal, it was conducted under a Rule 10b5-1 plan, mitigating concerns of opportunistic insider trading. The filing itself does not provide enough financial or strategic information to warrant a strong buy or sell recommendation, suggesting a 'hold' position pending further company disclosures.

Keywords

Werewolf Therapeutics, HOWL, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Director Transactions, Beneficial Ownership, MPM BioVentures, MPM Asset Management